[
  {
    "ts": null,
    "headline": "NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment",
    "summary": "NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.",
    "url": "https://finnhub.io/api/news?id=5f75353d14a9f34247a0facac67622024a5b049367567b15bfd73e8a1bafa4d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755612780,
      "headline": "NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment",
      "id": 136430245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.",
      "url": "https://finnhub.io/api/news?id=5f75353d14a9f34247a0facac67622024a5b049367567b15bfd73e8a1bafa4d9"
    }
  },
  {
    "ts": null,
    "headline": "Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares",
    "summary": "Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Learn more on SYK stock here.",
    "url": "https://finnhub.io/api/news?id=decb67703cc995e9e0df48acbbc74a25d0a291bfd08765daaf6f1fd0b8934898",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755611418,
      "headline": "Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares",
      "id": 136430816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/537016810/image_537016810.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Learn more on SYK stock here.",
      "url": "https://finnhub.io/api/news?id=decb67703cc995e9e0df48acbbc74a25d0a291bfd08765daaf6f1fd0b8934898"
    }
  },
  {
    "ts": null,
    "headline": "MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up",
    "summary": "Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.",
    "url": "https://finnhub.io/api/news?id=6a6f5b9ac0dc2be2d1d930e3120b7f7ee96d5816ee4290b6fd5a2f317a68ea55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755611280,
      "headline": "MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up",
      "id": 136430246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.",
      "url": "https://finnhub.io/api/news?id=6a6f5b9ac0dc2be2d1d930e3120b7f7ee96d5816ee4290b6fd5a2f317a68ea55"
    }
  },
  {
    "ts": null,
    "headline": "Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds",
    "summary": "COO leans on innovation and diversification to fuel growth, but fertility softness, tariffs and inventory headwinds weigh on near-term outlook.",
    "url": "https://finnhub.io/api/news?id=82ebbd1a928d9cf607f6150ea33bd9bcbdc10b9c5637dba42881547843e8d199",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755607800,
      "headline": "Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds",
      "id": 136430247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "COO leans on innovation and diversification to fuel growth, but fertility softness, tariffs and inventory headwinds weigh on near-term outlook.",
      "url": "https://finnhub.io/api/news?id=82ebbd1a928d9cf607f6150ea33bd9bcbdc10b9c5637dba42881547843e8d199"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up",
    "summary": "LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.",
    "url": "https://finnhub.io/api/news?id=b769f43d08e368495d6073f1bc0b58b5873c7502d2a5cb2af526f9888e8c7efe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755605100,
      "headline": "Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up",
      "id": 136430248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.",
      "url": "https://finnhub.io/api/news?id=b769f43d08e368495d6073f1bc0b58b5873c7502d2a5cb2af526f9888e8c7efe"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Global Opportunities Fund Q2 2025 Commentary",
    "summary": "Global markets turned in an impressive but volatile Q2, swinging from double-digit declines to double-digit gains. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=bf46fad3ecf3c23bdd59ce21342c4369f48913ccb08cd47dea00748f5b7646f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755587100,
      "headline": "Artisan Global Opportunities Fund Q2 2025 Commentary",
      "id": 136416659,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/530977027/image_530977027.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Global markets turned in an impressive but volatile Q2, swinging from double-digit declines to double-digit gains. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=bf46fad3ecf3c23bdd59ce21342c4369f48913ccb08cd47dea00748f5b7646f1"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Healthcare Fund Q2 2025 Commentary",
    "summary": "For 2Q25, Macquarie Healthcare Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 3000 Healthcare Index.",
    "url": "https://finnhub.io/api/news?id=655eb96db3e0f03d6d68a1ad112eac29691c479b1a0d5c889fa859d753088728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755581760,
      "headline": "Macquarie Healthcare Fund Q2 2025 Commentary",
      "id": 136416407,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2043764026/image_2043764026.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "For 2Q25, Macquarie Healthcare Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 3000 Healthcare Index.",
      "url": "https://finnhub.io/api/news?id=655eb96db3e0f03d6d68a1ad112eac29691c479b1a0d5c889fa859d753088728"
    }
  }
]